These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32442287)

  • 1. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
    Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y
    Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
    Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
    Front Immunol; 2021; 12():568789. PubMed ID: 34149679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.
    Minutolo A; Petrone V; Fanelli M; Maracchioni C; Giudice M; Teti E; Coppola L; Sorace C; Iannetta M; Tony Miele M; Bernardini S; Mastino A; Sinibaldi Vallebona P; Balestrieri E; Andreoni M; Sarmati L; Grelli S; Garaci E; Matteucci C
    Int Immunopharmacol; 2023 May; 118():110055. PubMed ID: 36989892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
    Mao L
    Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
    Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
    Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E
    J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
    Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S
    Int Immunopharmacol; 2021 Jan; 90():107022. PubMed ID: 33160854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Exhaustion Levels of NK and CD8
    Li M; Guo W; Dong Y; Wang X; Dai D; Liu X; Wu Y; Li M; Zhang W; Zhou H; Zhang Z; Lin L; Kang Z; Yu T; Tian C; Qin R; Gui Y; Jiang F; Fan H; Heissmeyer V; Sarapultsev A; Wang L; Luo S; Hu D
    Front Immunol; 2020; 11():580237. PubMed ID: 33154753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and immunological characteristics of COVID-19 patients with delayed SARS-CoV-2 virus clearance.
    Wang J; Li D; Tang B; Sun X; Shi W; Li H; Zhang Z; Wu Y; Zhang Y; Qiao Q
    Immun Inflamm Dis; 2023 Sep; 11(9):e999. PubMed ID: 37773701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection.
    Espinar-Buitrago MS; Vazquez-Alejo E; Magro-Lopez E; Tarancon-Diez L; Leal M; Muñoz-Fernandez MA
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111103. PubMed ID: 38149577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients.
    Shahbazi M; Moulana Z; Sepidarkish M; Bagherzadeh M; Rezanejad M; Mirzakhani M; Jafari M; Mohammadnia-Afrouzi M
    Microb Pathog; 2021 Apr; 153():104779. PubMed ID: 33548481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
    Liu J; Shen Y; Wen Z; Xu Q; Wu Z; Feng H; Li Z; Dong X; Huang S; Guo J; Zhang L; Chen Y; Li W; Zhu W; Du H; Liu Y; Wang T; Chen L; Teboul JL; Annane D; Chen D
    Front Immunol; 2021; 12():673693. PubMed ID: 34408744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model.
    Ricci D; Etna MP; Severa M; Fiore S; Rizzo F; Iannetta M; Andreoni M; Balducci S; Stefanelli P; Palamara AT; Coccia EM
    Int Immunopharmacol; 2023 Apr; 117():109996. PubMed ID: 36933449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of peripheral lymphocyte subsets and T-cell exhaustion in SARS-CoV-2 Infection.
    Soyyiğit Ş; Öksüzer Çimşir D; Öncül A; Pekel A; Öner Erkekol F; Güner R; İzdeş S; Gökmen D; Gökbulut Bektaş Ş; İnan O; Gemcioğlu E; Yılmaz A; Şahiner ES; Hasanoğlu İ; Kaya Kalem A; Kayaaslan B; Eser F; Ateş İ
    Tuberk Toraks; 2024 Jun; 72(2):152-166. PubMed ID: 38869208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age cohorts stratified according to age-distributions of COVID-19 morbidity statistics identify uniquely age-dependent CD3
    Jin S; An H; Zhou T; Li T; Chen C; Ying B; Xu Z; Li X; Li M
    Aging (Albany NY); 2021 Mar; 13(6):7713-7722. PubMed ID: 33714947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.
    Gozzi-Silva SC; Oliveira LM; Alberca RW; Pereira NZ; Yoshikawa FS; Pietrobon AJ; Yendo TM; de Souza Andrade MM; Ramos YAL; Brito CA; Oliveira EA; Beserra DR; Orfali RL; Aoki V; Duarte AJDS; Sato MN
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4
    Popescu I; Snyder ME; Iasella CJ; Hannan SJ; Koshy R; Burke R; Das A; Brown MJ; Lyons EJ; Lieber SC; Chen X; Sembrat JC; Bhatt P; Deng E; An X; Linstrum K; Kitsios G; Konstantinidis I; Saul M; Kass DJ; Alder JK; Chen BB; Lendermon EA; Kilaru S; Johnson B; Pilewski JM; Kiss JE; Wells AH; Morris A; McVerry BJ; McMahon DK; Triulzi DJ; Chen K; Sanchez PG; McDyer JF
    Am J Respir Crit Care Med; 2022 Jun; 205(12):1403-1418. PubMed ID: 35348444
    [No Abstract]   [Full Text] [Related]  

  • 18. Poor Survival in COVID-19 Associated with Lymphopenia and Higher Neutrophile-Lymphocyte Ratio.
    Montiel-Cervantes LA; Medina G; Pilar Cruz-Domínguez M; Pérez-Tapia SM; Jiménez-Martínez MC; Arrieta-Oliva HI; Carballo-Uicab G; López-Pelcastre L; Camacho-Sandoval R
    Isr Med Assoc J; 2021 Mar; 23(3):153-159. PubMed ID: 33734627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression.
    Mahmoodpoor A; Hosseini M; Soltani-Zangbar S; Sanaie S; Aghebati-Maleki L; Saghaleini SH; Ostadi Z; Hajivalili M; Bayatmakoo Z; Haji-Fatahaliha M; Babaloo Z; Farid SS; Heris JA; Roshangar L; Rikhtegar R; Kafil HS; Yousefi M
    Mol Immunol; 2021 Oct; 138():121-127. PubMed ID: 34392110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific dynamic variations in the peripheral blood lymphocyte subsets in COVID-19 and severe influenza A patients: a retrospective observational study.
    Qian F; Gao G; Song Y; Xu Y; Wang A; Wang S; Hao Y; Chen M; Ma X; Zhao T; Guo X; Chen Z; Zhang F
    BMC Infect Dis; 2020 Dec; 20(1):910. PubMed ID: 33261583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.